Qiagen N.V. Common Shares (NY:QGEN)

45.48 +0.73 (+1.63%)

Delayed Quote Updated: 1:45 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance ↗

May 06, 2022

Via Benzinga

QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System

May 05, 2022

From QIAGEN N.V.

Via Business Wire

Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook ↗

April 27, 2022

Via Benzinga

QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook

April 26, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to release results for Q1 2022 and hold Webcast

April 20, 2022

From QIAGEN N.V.

Via Business Wire

Earnings Scheduled For April 27, 2022 ↗

April 27, 2022

Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.

Via Benzinga

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

March 24, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces 20-F Annual Report Filing for 2021 Results

March 14, 2022

From QIAGEN N.V.

Via Business Wire

Death Cross Looms Over Qiagen Investors ↗

February 17, 2022

If history is any guide, there may be trouble ahead for shares of Qiagen (NYSE:QGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance ↗

February 09, 2022

Qiagen N.V. (NYSE: QGEN)

Via Benzinga

Qiagen: Q4 Earnings Insights ↗

February 08, 2022

Qiagen (NYSE:QGEN) reported its Q4 earnings results on Tuesday, February 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Qiagen beat estimated earnings by...

Via Benzinga

QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

February 08, 2022

From QIAGEN N.V.

Via Business Wire

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For February 8, 2022 ↗

February 08, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

Via Benzinga

Qiagen's Earnings: A Preview ↗

February 07, 2022

Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will likely...

Via Benzinga

QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

February 07, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes

January 27, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance

January 25, 2022

From QIAGEN N.V.

Via Business Wire

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021

January 19, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products

January 18, 2022

From QIAGEN N.V.

Via Business Wire

What Does Qiagen's Debt Look Like? ↗

January 13, 2022

Over the past three months, shares of Qiagen (NYSE:QGEN) moved lower by 5.06%. Before we understand the importance of debt, let us look at how much debt Qiagen has. Qiagen...

Via Benzinga

QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version

January 10, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

January 07, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

January 06, 2022

From QIAGEN N.V.

Via Business Wire

Free COVID Tests: What Stocks Will Benefit? ↗

December 23, 2021

The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits.

Via Talk Markets

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

December 09, 2021

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19

December 02, 2021

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.